Cardiometabolic
Treating hypertension in pregnancy is possible. Making it routine care is the policy challenge
A new ACC expert analysis sets out a practical approach to antihypertensive medication use in pregnancy and lactation, naming extended-release nifedipine and labetalol as preferred options in pregnancy, and nifedipine, amlodipine, enalapril and labetalol as preferred options during lactation. The clinical message is clear. The policy message is bigger: pregnant and postpartum patients need safe…
Ultra-processed food may leave a metabolic fingerprint in the blood.
Sugar substitutes were sold as metabolic shortcuts. The evidence is getting harder to ignore
Same country, different risks: why Iranian women’s heart disease profiles expose a blind spot in prevention policy
Menopause is a cardiometabolic checkpoint. Health systems still treat it like a hormone debate
GLP-1 drug choice now affects cardiovascular outcomes. Access and reimbursement rules have not caught up
MENA’s cardiometabolic crisis is a stability issue
Corxel’s oral GLP-1 trial adds momentum. The real question is who these drugs will reach
Half of CKM patients go untreated and most fail control
Sleep is now cardiovascular prevention. Health systems still treat it like lifestyle advice
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.